Loading...
Price History
Market Data
| Market Cap | 476,944.93 |
| P/E Ratio | - |
| P/B Ratio | 0.01 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 0.47 |
| Current Ratio | 4.85 |
| Currency | USD |
Key Financial Metrics
-
Revenue
29.82M
Net Income
-
EPS (Diluted)
-69.16M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
16.90M
Returns & Efficiency
Return on Assets (ROA)
48.3%
Return on Equity (ROE)
71.0%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
61.78M
Total Debt
-
Debt to Equity
0.47x
Current Ratio
4.85
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | WALTHAM, MA |
| Fiscal Year | 2025 |
Peers
LILLY ELI & CO
LLY
894.82B
P/E: --
ELI LILLY & CO
LLY
894.82B
P/E: --
533.28B
P/E: --
ABBVIE INC.
ABBV
355.49B
P/E: --
BEIGENE, LTD.
BEIGF
306.50B
P/E: 632.4
BEONE MEDICINES LTD.
BEIGF
306.50B
P/E: 632.4
275.14B
P/E: --
MERCK & CO. INC.
MRK
275.14B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$476.94K
P/E Ratio (TTM)-
Price to Book0.01
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE71.0%
ROA48.3%
Leverage & Liquidity
Debt to Equity0.47
Current Ratio4.85
Total Debt-
Total Assets$61.78M
Stockholders' Equity$42.01M
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$16.90M
Net Income$29.82M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-69.16M
Cash & Equivalents$48.30M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 830 WINTER STREET WALTHAM, MA 02451 |
| Phone | N/A |
| Incorporated | DE, US |
| EIN | 473468154 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 88,487.00 |
| Stockholders' Equity | $42.01M |
| Cash & Equivalents | $48.30M |
Recent Filings
View All
SCHEDULE 13D/A
Amended Schedule 13D
Amendment to Schedule 13D
Filed: 2026-05-06
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-05-06
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2026-05-05
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-05-05
Local
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-30
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-30
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-30
Local
S-8
Employee Plan Registration
Registration for employee benefit plan securities
Filed: 2026-03-10
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-10
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-10
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-02-17
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-02-17
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-02-13
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-13
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-06
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | Q32 Bio Inc. |
| Ticker | QTTB |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | WALTHAM, MA |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 476,944.93 |
| Revenue | - |
| Net Income | 29.82M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | - |
| ROE | 71.0% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...